SCHEMBL2845914

SCHEMBL2845914

CNC(=O)C(C)NC(=O)O

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
MMP1 P03956 1/20 0.33
ACE P12821 2/20 0.32
MME P08473 1/20 0.32
CPA1 P15085 1/20 0.32
ACE2 Q9BYF1 1/20 0.32
MMP9 P14780 3/20 0.32
MMP8 P22894 3/20 0.32
FFAR2 O15552 1/20 0.31
MMP2 P08253 2/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.30
GAA P10253 2/20 0.30
BMP1 P13497 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21638038 0.79 GAA (0.34) MMP1ACEMMECPA1ACE2
SCHEMBL21424045 0.79 ALDH1A1 (0.37) MMP1MMP9MMP8FFAR2MMP2
SCHEMBL14058708 0.79 MMP8 (0.39) CYP2D6CYP2C19MMP1MMP9MMP8
SCHEMBL15006102 0.79 ALDH1A1 (0.37) MMP1MMP9MMP8FFAR2MMP2
SCHEMBL13575189 0.79 ALDH1A1 (0.37) MMP1MMP9MMP8FFAR2MMP2
SCHEMBL25139840 0.79 GAA (0.34) MMP1ACEMMECPA1ACE2
SCHEMBL14365811 0.79 SMN1; SMN2 (0.34) MMP1MMP9MMP8FFAR2MMP2
SCHEMBL21153239 0.77 XIAP (0.38) MMP1ACEMMECPA1ACE2
SCHEMBL14076482 0.77 XIAP (0.38) MMP1ACEMMECPA1ACE2
SCHEMBL18520186 0.77 MAPT (0.42) FFAR2LMNAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115413275-A Substituted 1,1 , -biphenyl compounds and methods of use thereof 爱彼特生物制药公司 2022-11-29 CN disclosed
US-8232312-B2 Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-31 US disclosed
EP-2125718-B1 NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2010-09-15 EP disclosed
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130557-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PYGL, PYGM, G6PC1 CYP2D6 503/4885CYP2C19 628/4885MMP1 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.